This is not the most recent version of the article. View current version (7 JUL 2010)

Intervention Protocol

Evaluation of the efficacy and safety of adjunct treatment to levodopa therapy in Parkinson's disease patients with motor complications

  1. Rebecca Stowe1,*,
  2. Natalie Ives1,
  3. Carl E Clarke2,
  4. Katherine Deane3,
  5. van Hilten4,
  6. Keith Wheatley5,
  7. Richard Gray6

Editorial Group: Cochrane Movement Disorders Group

Published Online: 23 APR 2008

DOI: 10.1002/14651858.CD007166


How to Cite

Stowe R, Ives N, Clarke CE, Deane K, van Hilten, Wheatley K, Gray R. Evaluation of the efficacy and safety of adjunct treatment to levodopa therapy in Parkinson's disease patients with motor complications (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007166. DOI: 10.1002/14651858.CD007166.

Author Information

  1. 1

    University of Birmingham, University of Birmingham Clinical Trials Unit, Birmingham, UK

  2. 2

    City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Department of Neurology, Birmingham, West Midlands, UK

  3. 3

    Newcastle University, Institute of Health & Society, Newcastle-upon-Tyne, UK

  4. 4

    Leiden University of Medical Center, Department of Neurology, Leiden, Netherlands

  5. 5

    Robert Aitken Institute University of Birmingham, Birmingham Clinical Trials Unit - Division of Medical Sciences, Birmingham, UK

  6. 6

    The University of Birmingham, Clinical Trials Unit, Edgbaston, Birmingham, UK

*Rebecca Stowe, University of Birmingham Clinical Trials Unit, University of Birmingham, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham, B15 2TT, UK. r.l.harrison@bham.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 APR 2008

SEARCH

This is not the most recent version of the article. View current version (07 JUL 2010)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

This 'umbrella' systematic review aims to compare the effectiveness and safety of the three main classes of add-on drugs that are used in later PD. This will involve comparing the efficacy and safety of dopamine agonist, COMTI and MAOBI add-on therapy versus placebo in the management of patients with later PD who are on established levodopa therapy and suffering from motor complications.

Alongside the process of producing the umbrella review, we will perform updates of individual Cochrane adjuvant therapy reviews (Clarke 1999a; Clarke 1999b; Clarke 2000; Clarke 2001a; Clarke 2001b; Deane 2004; van Hilten 1998). Thus, the project will complement previous individual reviews by updating and clarifying the existing evidence base as well as provide important information as to the class effects of add-on therapy in later PD.